Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI and home monitoring could help diabetes patients see their risks clearly

NCT ID NCT06607497

Disease control Sponsor: SingHealth Polyclinics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an AI tool that shows patients how their blood sugar control compares to others, combined with home monitoring, can improve risk perception and blood sugar levels in adults with poorly controlled type 2 diabetes. About 360 participants aged 36–65 will be split into three groups: one gets the AI tool plus home monitoring, one gets only the AI tool, and one gets usual care. The goal is to see if these tools help people better understand their risks and take action to improve their health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-enabled risk communication tool (PERDICT.AI) and telemonitoring system (PTEC-DM)
What this could lead to
If successful, this approach could help people with type 2 diabetes better understand their personal risks and improve blood sugar control, potentially reducing complications.
What could go wrong
This is a relatively small, early-stage trial focused on behavior and perception, not a direct treatment. The improvements may be modest or not sustained, and results may not apply to all diabetes patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

360 people

The number who actually took part.

Started

Jul 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

36 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Type 2 Diabetes Mellitus on follow-up at the study site for at least 12 months * Age 36 to 65 years * At least one HbA1c reading ≥ 8.0% within the last 6 months * Able to read and speak English Exclusion Criteria: * Not a Singapore citizen or permanent resident * Pregnant * End-stage kidney disease or on renal replacement therapy * Known terminal illness * Visual and/or hearing impairment * Cognitive impairment or mental illness * Unable to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

Contacts and locations

Locations

  • SingHealth Polyclinics

    Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.